North China Pharmaceutical Co (SHSE:600812) Loans Receivable: ¥ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600812 North China Pharmaceutical Co Ltd SHSE:600812
57 GF Score
Price ¥5.08
GF Value ¥4.59
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is North China Pharmaceutical Co Loans Receivable?

North China Pharmaceutical Co SHSE:600812 +9.96% 57 Loans Receivable is ¥ Mil as of Jun. 2026. GuruFocus rates SHSE:600812 with a GF Score™ of 57/100 and a GF Value™ of ¥4.59 (Modestly Overvalued). The stock has 9 warning signs investors should review.

North China Pharmaceutical Co's Loans Receivable for the quarter that ended in Jun. 2026 was ¥ Mil.

North China Pharmaceutical Co Loans Receivable Related Terms

North China Pharmaceutical Co Loans Receivable Historical Data

* Premium members only.

The historical data trend for North China Pharmaceutical Co's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

North China Pharmaceutical Co Loans Receivable Chart

North China Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

North China Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
SHSE:600812
57GF Score
North China Pharmaceutical Co Ltd SHSE:600812
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

North China Pharmaceutical Co Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of ¥ Mil mean?
North China Pharmaceutical Co (SHSE:600812) has a Loans Receivable of ¥ Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on North China Pharmaceutical Co and its competitors.
Is North China Pharmaceutical Co's Loans Receivable too high?
North China Pharmaceutical Co's current Loans Receivable is ¥ Mil. Overall, North China Pharmaceutical Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does North China Pharmaceutical Co's Loans Receivable compare to ZTS?
North China Pharmaceutical Co's Loans Receivable of ¥ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on North China Pharmaceutical Co and its competitors. North China Pharmaceutical Co's current Loans Receivable is ¥ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is North China Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, North China Pharmaceutical Co (SHSE:600812) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥4.59, compared to a current price of ¥5.08 — trading 10.7% above its estimated fair value. The current Loans Receivable is ¥ Mil. North China Pharmaceutical Co's overall GF Score™ is 57/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For North China Pharmaceutical Co (SHSE:600812), the current Loans Receivable is ¥ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is North China Pharmaceutical Co (SHSE:600812) Overvalued in 2026?

Based on GuruFocus' analysis, North China Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥5.08 is trading 10.7% above its estimated GF Value™ of ¥4.59. GuruFocus considers North China Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600812:

  • Loans Receivable: ¥ Mil
  • GF Value™: ¥4.59 vs. price of ¥5.08 (10.7% above fair value)
  • GF Score™: 57/100 with 9 warning signs

No single metric tells the full story. See the SHSE:600812 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

North China Pharmaceutical Co Business Description

Address No. 388 Heping East Road, Shijiazhuang, Hebei, CHN, 050015
North China Pharmaceutical Co Ltd is engaged in the manufacture and sale of antibiotics, vitamins, and pharmaceutical products in China. The main products include antibiotics such as penicillin, vitamins, cephalosporins, streptomycin, biotechnological drugs, new preparations, and biological products.
57GF Score

Get the complete analysis for SHSE:600812

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.08
Price
¥4.59
GF Value